PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)--Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company will file its financial results for the three and six months ended June 30, 2016 on Form 6K with the U.S. Securities and Exchange Commission (“SEC”) after the closing of the U.S. financial markets on September 26, 2016. The Form 6K will include unaudited consolidated financial statements, as well as additional information regarding the Company. The Form 6K will be available at www.sec.gov and at www.rosettagenomics.com.